TC 1734 fails Phase IIb trial for Alzheimers disease - Targacept Inc.
Targacept, Inc. a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, has announced top-line results from a Phase IIb monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer�s Disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer�s disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.
The firm does not intend to invest in further development of TC-1734.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins